Physicians

Division Chief, Endocrinology, Metabolism, and Nutrition

Departments / Divisions

• Medicine / Med - Endocrinology & Metab
• Pathology
• Psychiatry

Address
DUMC 3921
Durham, NC 27710

Appointment Telephone
919-668-7630

Office Telephone
919-684-4005

Fax Telephone
919-681-8477

Training

• MD, CM, McGill University Faculty of Medicine (Canada), 1973

Residency

• Internal Medicine, Duke University Medical Center, 1973-1975

Fellowship

• Endocrinology, Duke University Medical Center, 1975-1978

Clinical Interests
Diabetes mellitus, with particular interest in patients with unstable diabetes, insulin resistance, insulin allergy, poorly controlled type 2 diabetes, hypothyroidism, hyperthyroidism

Research Interests
I am interested in the etiology and treatment of type 2 diabetes mellitus.  For many years, we have studied the role of the autonomic nervous system in the pathophysiology of type 2 siabetes in humans and a murine model.  We have also studied the mechanism of action of dietary therapy and a variety of pharmacological agents in the treatment of type 2 diabetes.

Dr. Richard Surwit of the Department of Psychiatry and Behavioral Sciences and I are conducting a variety of human studies on the relationship of stress hormones and various food additives on the development and expression of type 2 diabetes. I am also engaged in a number of multicenter studies of the effect of various treatment plans  on cardiovascular outcome in type 2 diabetes patients.  In addtion, my group continues to evaluate new treatment modalities for patients with type 2 diabetes, including new types of insulin, GLP-1 analogs, new classes of oral agents, and combinations of drugs.

I am frequently consulted by industry to evaluate new therapeutic modalities.  I most frequently peer review scientific articles concerning the treatment of type 2 diabetes.

Key words:  diabetes mellitus, stress, sulfonylureas, oral hypoglycemics, insulin, murine diabetes, diabetic diet

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• GlaxoSmithKline
• Pfizer Inc.

Representative Publications
Luna B., Feinglos, M.N.: Drug-induced Hyperglycemia. JAMA-J. Am. Med. Assoc. 286/16:1945-1948, 2001. (2001)

Feinglos, M.N., Thacker, C.H., English, J.S., Bethel, M.A., Lane, J.D.: Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 20:1539-1542, 1997. (1997)

Surwit, R.S., Seldin, M.F., Kuhn, C.M., Cochrane, C., and Feinglos, M.N.: Different genetic factors control the expression of insulin resistance and hypoglycemia in diabetic C57BL/6J mice. Diabetes 40:82-87, 1991. (1991)

Feinglos, M.N., Hastedt, P., Surwit, R.S.: The effects of relaxation therapy on patients with type I diabetes mellitus. Diabetes Care 10:72-75, 1987. (1987)

Feinglos, M.N. and Lebovitz, H.E.: Sulfonylureas increase the number of insulin receptors. Nature 276:184-185, 1978. (1978)